ASCO 2017 | An overview of the potential of immunotherapy in treating lymphoma
Anas Younes, MD, from the Memorial Sloan-Kettering Cancer Center, New York, NY, discusses immunotherapy in the treatment of lymphoma, namely the use of checkpoint inhibitors, CAR T-Cells and a bispecific platform between antibodies and CAR T-cells whereby antibodies are used to bring immune cells to sites of disease. Here, he also discusses the potential of applying genetic research to identify biomarkers of lymphoma. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
Get great new content delivered to your inboxSign up